Cerebrolysin and repetitive transcranial magnetic stimulation (rTMS) in patients with traumatic brain injury: a three-arm randomized trial.

Verisezan Rosu O, Jemna N, Hapca E, Benedek I, Vadan I, Muresanu I, Chira D, Radu C, Cherecheş R, Strilciuc S, Muresanu D

Frontiers in neuroscience8 Jun 2023Cited by 10 (Europe PMC)

PMID37360156PMCIDPMC10285097DOI10.3389/fnins.2023.1186751PepBankPUB-37360156

Download PDF PubMedAsk about this study

Jump to 2 results

Summary

IntroductionTraumatic brain injury (TBI) is a major public health problem affecting millions worldwide. Despite significant advances in medical care, there are limited effective interventions for improving cognitive and functional outcomes in TBI patients.MethodsThis randomized controlled trial investigated the safety and efficacy of combining repetitive transcranial magnetic stimulation (rTMS) and Cerebrolysin in improving cognitive and functional outcomes in TBI patients. Ninety-three patients with TBI were randomized to receive either Cerebrolysin and rTMS (CRB + rTMS), Cerebrolysin and sham stimulation (CRB + SHM), or placebo and sham stimulation (PLC + SHM). The primary outcome measures were the composite cognitive outcome scores at 3 and 6 months after TBI. Safety and tolerability were also assessed.ResultsThe study results demonstrated that the combined intervention of rTMS and Cerebrolysin was safe and well-tolerated by patients with TBI. Although no statistically significant differences were observed in the primary outcome measures, the descriptive trends in the study support existing literature on the efficacy and safety of rTMS and Cerebrolysin.DiscussionThe findings of this study suggest that rTMS and Cerebrolysin may be effective interventions for improving cognitive and functional outcomes in TBI patients. However, limitations of the study, such as the small sample size and exclusion of specific patient populations, should be considered when interpreting the results. This study provides preliminary evidence for the safety and potential efficacy of combining rTMS and Cerebrolysin in improving cognitive and functional outcomes in TBI patients. The study highlights the importance of multidisciplinary approaches in TBI rehabilitation and the potential for combining neuropsychological measurements and interventions to optimize patient outcomes.ConclusionFurther research is needed to establish these findings' generalizability and identify the optimal dosages and treatment protocols for rTMS and Cerebrolysin.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

01HumanNot a test of Cerebrolysin aloneRandomized controlled trialEfficacy outcome
In patients with traumatic brain injury, composite cognitive outcome scores at 3 and 6 months did not differ significantly across Cerebrolysin/rTMS, Cerebrolysin/sham, and placebo/sham groups.
In plain wordsIn brain injury patients, cognitive scores at 3 and 6 months did not differ significantly across Cerebrolysin/rTMS, Cerebrolysin/sham, and placebo/sham groups.
Peptide
Cerebrolysin
Outcome
No significant changeComposite cognitive outcome scores at 3 and 6 months
Study
n = 93
Comparator
Cerebrolysin plus rTMS, Cerebrolysin plus sham, and placebo plus sham groups
Analysis
Primary
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
Although no statistically significant differences were observed in the primary outcome measures, the descriptive trends in the study support existing literature on the efficacy and safety of rTMS and Cerebrolysin.
2 context sentences(design, population, supporting numbers)
Summary · context
The primary outcome measures were the composite cognitive outcome scores at 3 and 6 months after TBI.
Summary · context
Ninety-three patients with TBI were randomized to receive either Cerebrolysin and rTMS (CRB + rTMS), Cerebrolysin and sham stimulation (CRB + SHM), or placebo and sham stimulation (PLC + SHM).
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Show in the study text Report a problemFND-3736015602
02HumanNot a test of Cerebrolysin aloneRandomized controlled trialSafety outcome
In patients with traumatic brain injury, combined rTMS and Cerebrolysin was safe and well tolerated.
In plain wordsIn patients with brain injury, combined rTMS and Cerebrolysin was safe and well tolerated.
Peptide
Cerebrolysin
Outcome
Not applicableSafety and tolerability
Study
n: not reported in source
Outcome group
Adverse events · Nervous system and cognition
Source sentences
Summary
The study results demonstrated that the combined intervention of rTMS and Cerebrolysin was safe and well-tolerated by patients with TBI.
1 context sentence(design, population, supporting numbers)
Summary · context
Ninety-three patients with TBI were randomized to receive either Cerebrolysin and rTMS (CRB + rTMS), Cerebrolysin and sham stimulation (CRB + SHM), or placebo and sham stimulation (PLC + SHM).
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Show in the study text Report a problemFND-3736015601

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.